These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1612787)

  • 1. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors.
    Mattijssen V; Balemans LT; Steerenberg PA; De Mulder PH
    Int J Cancer; 1992 Jul; 51(5):812-7. PubMed ID: 1612787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.
    Balemans LT; Mattijssen V; Steerenberg PA; Van Driel BE; De Mulder PH; Den Otter W
    Cancer Immunol Immunother; 1993 Jul; 37(1):7-14. PubMed ID: 8513455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide.
    Balemans LT; Steerenberg PA; Koppenhagen FJ; Kremer BH; De Mulder PH; Claessen AM; Scheper RJ; Den Otter W
    Int J Cancer; 1994 Sep; 58(6):871-6. PubMed ID: 7927881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.
    Bernsen MR; Dullens HF; Den Otter W; Heintz PM
    J Interferon Cytokine Res; 1995 Jul; 15(7):641-5. PubMed ID: 7553236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells.
    Balemans LT; Steerenberg PA; Kremer BH; Koppenhagen FJ; De Mulder PH; Den Otter W
    Cancer Immunol Immunother; 1995 Feb; 40(2):125-31. PubMed ID: 7882383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma].
    Wang L; Wu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):253-5. PubMed ID: 9387313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional low-dose interleukin-2 immunotherapy of lymph node micrometastasis in a guinea pig tumor model.
    Bier H; Haas I; Koldowski P
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(2):96-100. PubMed ID: 8177593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.
    Zimmerman RJ; Aukerman SL; Katre NV; Winkelhake JL; Young JD
    Cancer Res; 1989 Dec; 49(23):6521-8. PubMed ID: 2819708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vivo antitumor activities of polyethylene glycol modified recombinant interleukin 2 (PEG-rIL-2) against murine hepatoma].
    Feng XS
    Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):256-8. PubMed ID: 8174461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of interleukin-1 beta in the double grafted tumor system.
    Ebina T; Ishikawa K
    Jpn J Cancer Res; 1989 Jun; 80(6):570-6. PubMed ID: 2503477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
    Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
    Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma.
    Claessen AM; Bloemena E; Bril H; Meijer CJ; Scheper RJ
    Cancer Res; 1992 May; 52(9):2440-6. PubMed ID: 1568214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma.
    Mattijssen V; De Mulder PH; De Graeff A; Hupperets PS; Joosten F; Ruiter DJ; Bier H; Palmer PA; Van den Broek P
    Ann Oncol; 1994 Dec; 5(10):957-60. PubMed ID: 7696170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.
    Ootsu K; Gotoh K; Houkan T
    Cancer Immunol Immunother; 1989; 30(2):71-80. PubMed ID: 2598180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system.
    Kikuchi T; Joki T; Saitoh S; Hata Y; Abe T; Kato N; Kobayashi A; Miyazaki T; Ohno T
    Int J Cancer; 1999 Jan; 80(3):425-30. PubMed ID: 9935185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
    Katre NV
    J Immunol; 1990 Jan; 144(1):209-13. PubMed ID: 2295792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.